VC Investment More Than Doubles in Q2, Driven by Megadeals

06:41 EDT 13 Jul 2018 | Genetic Engineering News

Investor appetite for “megadeals” of $100 million or more grew during the second quarter, helping explain why biopharma venture capital investment more than doubled compared with a year ago, even as the number of deals stayed flat, according to a report released this week. Investors raised $4.047 billion in 126 biopharma VC deals during Q2 2018, according to the most recent quarterly PwC/CB Insights MoneyTree™ Report. That’s 117% above the $1.867 billion recorded for the second three months of 2017. And while the number of deals in Q2 2017 was slightly higher at 128, the biopharma dollar and deal numbers may ultimately be higher than recorded, because they do not include a handful of “stealth mode” investments also recorded in the “healthcare” sector, for which details are unavailable. A total $68.46 million was invested in three stealth-mode startups during the second quarter, up nearly two-thirds in dollars ...

Original Article: VC Investment More Than Doubles in Q2, Driven by Megadeals


More From BioPortfolio on "VC Investment More Than Doubles in Q2, Driven by Megadeals"

Quick Search


Relevant Topic

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...